OpGen (OPGN) Downgraded to “Hold” at Zacks Investment Research
OpGen (NASDAQ:OPGN) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Tuesday.
According to Zacks, “OpGen, Inc. is a microbial genetics analysis company. The Company offers optical mapping services for analysis of microbial, yeast and fungal genomic architecture. OpGen, Inc. headquartered in Gaithersburg, Maryland. “
OPGN has been the subject of a number of other reports. ValuEngine downgraded shares of OpGen from a “sell” rating to a “strong sell” rating in a research report on Thursday, January 25th. HC Wainwright lifted their price target on shares of OpGen to $9.00 and gave the company a “buy” rating in a research report on Wednesday, February 7th.
An institutional investor recently raised its position in OpGen stock. Vanguard Group Inc. grew its stake in shares of OpGen Inc (NASDAQ:OPGN) by 1.6% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 342,860 shares of the medical research company’s stock after acquiring an additional 5,500 shares during the period. Vanguard Group Inc. owned about 1.25% of OpGen worth $219,000 at the end of the most recent reporting period.
TRADEMARK VIOLATION WARNING: “OpGen (OPGN) Downgraded to “Hold” at Zacks Investment Research” was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this piece of content on another publication, it was stolen and republished in violation of United States & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.dailypolitical.com/2018/03/14/opgen-opgn-downgraded-to-hold-at-zacks-investment-research.html.
OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.